Sequel Develops Novel Insulin Delivery System in Next Wave of Diabetes Innovation

episode

Vanguards of Healthcare by Bloomberg Intelligence not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

More from Vanguards of Healthcare by Bloomberg Intelligence

Athenahealth's Strategic Reset, Push for Speed in Ambulatory Care 53 min · 02 Apr 2026

Inside Insilico Medicine’s AI Strategy and Lilly Breakthrough 1h 2m · 31 Mar 2026

Abridge Moving AI From Scribing to Clinical Workflows 54 min · 26 Mar 2026

7Wire's Jaffee on the Hard Truths Behind Health-Tech Investing 44 min · 19 Mar 2026

Xaira’s War on Trial-and-Error Drug Development 56 min · 12 Mar 2026

AVS’ Toland on Next Lithotripsy Launch 43 min · 05 Mar 2026

All episodes from Vanguards of Healthcare by Bloomberg Intelligence →

Report any issue

Source

Recorded05 Dec 2024

Publisheromnycontent.com ↗

Handlerec:13806568

Show notes

Sequel is combining the experience of its four co-founders to develop the next generation of insulin pumps, aiming to provide better delivery capabilities, CEO Alan Lotvin tells Bloomberg Intelligence. In this Vanguards of Health Care podcast episode, Lotvin sits down with BI analyst Matt Henriksson for an in-depth interview on the path insulin pumps have taken over the past 50 years to close in on a truly automated delivery system. They also discuss Sequel’s development of its twiist delivery system, designed to better titrate insulin injected into the body, and its strategy for commercial launch in 2025.See omnystudio.com/listener for privacy information.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Sign in